Document Detail

Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats.
MedLine Citation:
PMID:  20359859     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: We hypothesized that carvedilol, a nonselective β-blocker, can exert antiarrhythmogenic effects by inhibiting sympathetic nerve sprouting and electrical remodeling at peri-infarct zones after myocardial infarction (MI).
METHODS: MI was induced by ligation of the coronary artery. The rats in the carvedilol group received 5.0mg/kg carvedilol twice a day. Eight weeks after MI, monophasic action potential duration (MAPD), effective refractory period (ERP) and the inducibility of ventricular arrhythmia at the peri-infarct zones were evaluated and compared with MI rats. After these studies, the expression of growth associated protein 43 (GAP43) and tyrosinehydroxylase (TH) at the peri-infarct zones were examined by western blot and RT-PCR analysis.
RESULTS: Eight weeks after surgery, carvedilol shortened the duration of the MAPD determined as 20% (MAPD(20)) and 90% (MAPD(90)) repolarization time (33 ± 9 ms and 110 ± 18 ms vs 21 ± 6 ms and 76 ± 13 ms, both P<0.05) and ERP (76 ± 15 ms vs 62 ± 12 ms, P<0.05), respectively. Carvedilol decreased the inducibility of ventricular arrhythmia after MI (76% vs 32%, P<0.05). The expression of GAP43 and TH were suppressed by carvedilol after MI.
CONCLUSION: Carvedilol exerts antiarrhythmogenic effects by ameliorating sympathetic nerve sprouting and electrical remodeling in MI rats. The effects of carvedilol on amelioration of electrical remodeling may be partly related to the inhibition of sympathetic remodeling.
Huazhi Wen; Hong Jiang; Zhibing Lu; Xiaorong Hu; Bo He; Qizhu Tang; Congxin Huang
Related Documents :
15358019 - The pathologic basis of q-wave and non-q-wave myocardial infarction: a cardiovascular m...
16731479 - Spatial distribution of nerve sprouting after myocardial infarction in mice.
15764619 - Timi, pursuit, and grace risk scores: sustained prognostic value and interaction with r...
22956509 - Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute...
10636269 - Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial i...
16478749 - Incidence of recognized and unrecognized myocardial infarction in men and women aged 55...
22438429 - Long-term follow-up of attenuated plaques in patients with acute myocardial infarction:...
10933369 - Sarcolemmal na+/h+ exchanger activity and expression in human ventricular myocardium.
8752809 - The dd genotype of the angiotensin-converting enzyme gene is associated with increased ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-25
Journal Detail:
Title:  Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie     Volume:  64     ISSN:  1950-6007     ISO Abbreviation:  Biomed. Pharmacother.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-13     Completed Date:  2011-02-14     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8213295     Medline TA:  Biomed Pharmacother     Country:  France    
Other Details:
Languages:  eng     Pagination:  446-50     Citation Subset:  IM    
Copyright Information:
2010 Elsevier Masson SAS. All rights reserved.
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, 238, Jiefang Road, Wuchang, Wuhan 430060, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Action Potentials
Adrenergic beta-Antagonists / pharmacology*
Arrhythmias, Cardiac / metabolism,  physiopathology
Autonomic Pathways / metabolism,  physiopathology
Carbazoles / pharmacology*
GAP-43 Protein / metabolism
Heart / innervation,  physiopathology
Myocardial Infarction / drug therapy*,  metabolism,  physiopathology
Propanolamines / pharmacology*
RNA, Messenger / metabolism
Random Allocation
Rats, Wistar
Sympathetic Nervous System / drug effects*,  physiopathology
Tyrosine 3-Monooxygenase / metabolism
Ventricular Remodeling / drug effects
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/GAP-43 Protein; 0/Propanolamines; 0/RNA, Messenger; 0K47UL67F2/carvedilol; EC 3-Monooxygenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing p...
Next Document:  Comparison of voice-use profiles between elementary classroom and music teachers.